AKT1 and idiopathic pulmonary fibrosis: Considering the ineffectiveness of existing drugs, the toxicity of PI3K inhibitors and the role of Akt hyperactivation in fibrosis progression, targeting Akt through pharmacological inhibition offers a new therapeutic approach for IPF.